Acrivon Therapeutics, Inc. (ACRV) Tops Q3 EPS by 69c

Acrivon Therapeutics, Inc. (NASDAQ: ACRV) reported Q3 EPS of ($0.47), $0.69 better than the analyst estimate of ($1.16).

For earnings history and earnings-related data on Acrivon Therapeutics, Inc. (ACRV) click here.

You May Also Be Interested In

• Blue Owl leads $2.4 billion debt deal for Iren data center
• Flowers Foods (FLO) files mixed shelf
• BiomX announces 1-for-10 reverse stock split effective Sept. 9